MiNK Therapeutics与威斯康星大学麦迪逊分校共同宣布，正式启动针对同种异体iNKT细胞疗法（代号Agent-797）的一期临床试验。该试验旨在评估该疗法在预防移植物抗宿主病方面的潜在疗效与安全性。
这项合作将结合MiNK Therapeutics在细胞治疗领域的专业经验，以及威斯康星大学麦迪逊分校在免疫学与临床研究方面的学术优势。Agent-797作为一种创新疗法，有望为接受异体造血干细胞移植的患者提供新的免疫调控策略。
研究团队将密切关注试验进展，期待为移植物抗宿主病的预防开辟新的治疗路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.